John Fesko Sells 784 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider John Fesko sold 784 shares of the business’s stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $240.53, for a total transaction of $188,575.52. Following the completion of the transaction, the insider owned 176,468 shares of the company’s stock, valued at $42,445,848.04. This trade represents a 0.44% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

John Fesko also recently made the following trade(s):

• On Wednesday, January 28th, John Fesko sold 928 shares of Natera stock. The shares were sold at an average price of $237.66, for a total transaction of $220,548.48.
• On Wednesday, January 21st, John Fesko sold 339 shares of Natera stock. The shares were sold at an average price of $235.00, for a total transaction of $79,665.00.
• On Tuesday, January 20th, John Fesko sold 17,806 shares of Natera stock. The stock was sold at an average price of $234.74, for a total value of $4,179,780.44.

Natera Stock Performance

NASDAQ:NTRA traded down $4.45 during trading hours on Thursday, hitting $231.48. The stock had a trading volume of 947,123 shares, compared to its average volume of 1,043,018. Natera, Inc. has a one year low of $125.38 and a one year high of $256.36. The business’s 50 day moving average is $235.90 and its 200-day moving average is $193.29. The company has a market cap of $32.02 billion, a price-to-earnings ratio of -101.08 and a beta of 1.62.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). The company had revenue of $592.18 million during the quarter, compared to the consensus estimate of $514.55 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The business’s quarterly revenue was up 34.7% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.26) EPS. On average, sell-side analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Hedge Funds Weigh In On Natera

Large investors have recently bought and sold shares of the stock. Horizon Investments LLC purchased a new stake in shares of Natera during the third quarter valued at approximately $32,000. Hilltop National Bank purchased a new stake in Natera during the second quarter valued at about $33,000. Sound Income Strategies LLC boosted its holdings in Natera by 95.7% in the 3rd quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock worth $39,000 after buying an additional 110 shares during the period. Flagship Harbor Advisors LLC purchased a new position in shares of Natera in the fourth quarter valued at $41,000. Finally, Quent Capital LLC purchased a new position in Natera during the 3rd quarter valued at about $46,000. 99.90% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

NTRA has been the topic of several research analyst reports. BNP Paribas Exane raised shares of Natera to a “hold” rating and set a $172.00 price target on the stock in a report on Monday, October 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a research report on Thursday, January 22nd. Canaccord Genuity Group reiterated a “buy” rating on shares of Natera in a research report on Monday, January 12th. Zacks Research raised shares of Natera from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st. Finally, Guggenheim lifted their target price on shares of Natera from $230.00 to $270.00 and gave the stock a “buy” rating in a research report on Monday, January 5th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Natera has an average rating of “Moderate Buy” and a consensus price target of $249.20.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.